Cancer and Leukemia Group B

癌症和白血病 B 组

• 批准号: 8450282
• 负责人: CLIFFORD A HUDIS
• 金额: $ 19.47万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-30 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8450282
• 关键词: Ally; Area; Basic Science; Cancer Center; Cancer Hospital; Cancer and Leukemia Group B; Clinical; Clinical Research; Commit; Detection; Diagnosis; Disease; Grant; Hospitals; Institutes; Institution; Intention; Laboratories; Leadership; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Modality; Outpatients; Patient Care; Patients; Physicians; Policies; Positioning Attribute; Prevention; Research; Research Personnel; Research Training; Scientist; Testing; Training Programs; anticancer research; base; design; patient population; programs; research facility; success

DESCRIPTION (provided by applicant): Memorial Sloan-Kettering Cancer Center (MSKCC) is the largerst privately owneed nonprofit cancer center in the world. The Center consists of 3 corporations. Memorial Hospital for Cancer and Allied Diseases, foundin in 1884 is the clinical unit; Sloan-Kettering Institute for Cancer Research, founded in 1945 is the basic research unit; and Memorial Sloan-Kettering Cancer Center, founded in 1960 is the unit that formulates policies and long-range plans and coordinates the activities of the hospital and the institute. MSKCC is a free-standing institution committed to exceptional in-patient and out-patient care, leading edge research and superb clinical and research training programs. MSKCC's clinical research programs are synonymous with those of the Cancer and Leukemia Group B (CALGB). Physician-scientists at MSKCC hold leadership positions in the CALGB across an array of disease-specific areas and treatment modalities, with significant administrative responsibilities for the group. Scientific and clinical research programs at MSKCC are created with the intention of ultimately testing them, when possible, in the larger patient populations offered by our participation in the CALGB. During the next six years, MSKCC will continue to expand its clinical and research facilities as well as its research and training programs. The enclosed grant offers examples of MSKCC contributions to the success of the CALGB and support for MSKCC's continued participation.

描述（由申请人提供）：纪念斯隆-凯特琳癌症中心 (MSKCC) 是世界上最大的私营非营利性癌症中心。该中心由 3 个公司组成。癌症及相关疾病纪念医院成立于 1884 年，是临床单位；斯隆-凯特琳癌症研究所成立于1945年，是基础研究单位；纪念斯隆-凯特琳癌症中心成立于 1960 年，是制定政策和长期计划并协调医院和研究所活动的单位。 MSKCC 是一家独立机构，致力于提供卓越的住院和门诊护理、前沿研究以及一流的临床和研究培训项目。 MSKCC 的临床研究项目与癌症和白血病 B 组 (CALGB) 的临床研究项目是同义词。 MSKCC 的医师科学家在 CALGB 的一系列特定疾病领域和治疗方式中担任领导职务，并对该小组负有重要的行政责任。 MSKCC 的科学和临床研究项目的目的是最终在可能的情况下在我们参与 CALGB 所提供的更大的患者群体中进行测试。未来六年，MSKCC 将继续扩大其临床和研究设施以及研究和培训项目。随附的赠款提供了 MSKCC 对 CALGB 成功所做贡献以及对 MSKCC 持续参与的支持的示例。

项目成果

Omega-3 fatty acids for the prevention of breast cancer: an update and state of the science.

• DOI: 10.1007/s12609-013-0112-1
• 发表时间: 2013-09-01
• 期刊: CURRENT BREAST CANCER REPORTS
• 影响因子: 0.9
• 作者: Iyengar, Neil M;Hudis, Clifford A;Gucalp, Ayca
• 通讯作者: Gucalp, Ayca

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

替莫唑胺和沙利度胺治疗脑转移性黑色素瘤患者的 II 期研究：血栓栓塞事件发生率高 (CALGB 500102)。

• DOI: 10.1002/cncr.22239
• 发表时间: 2006
• 期刊: Cancer
• 影响因子: 6.2
• 作者: Krown,SusanE;Niedzwiecki,Donna;Hwu,Wen-Jen;Hodgson,Lydia;Houghton,AlanN;Haluska,FrankG;CancerandLeukemiaGroupB
• 通讯作者: CancerandLeukemiaGroupB

Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.

• DOI: 10.1002/pon.2094
• 发表时间: 2013-02
• 期刊: PSYCHO-ONCOLOGY
• 影响因子: 3.6
• 作者: Herndon, James E., II;Kornblith, Alice B.;Holland, Jimmie C.;Paskett, Electra D.
• 通讯作者: Paskett, Electra D.